VUPLENTIC

VUPLENTIC

Em análise

Nominativa · Brasil

Outros setores

Marca em análise: acompanhe a evolução

A marca "VUPLENTIC" ainda está em análise e o status pode mudar. Se o nome é próximo ao seu, pode ser útil acompanhar o desfecho e os despachos publicados.

Panorama da marca

Situação INPI
Aguardando exame de mérito
Idade do processo
1 ano
Eventos no processo
2
Última atualização
21 de janeiro de 2026

Dados do processo

Titular
Glaxo Group Limited
Número do processo
501871391
Número de registro
501871391
Natureza
Madri Produto/Serviço
Data do depósito
02 de julho de 2025
Válido até
09 de outubro de 2025

Produtos e serviços cobertos

Classe 5Outros setores

Pharmaceutical preparations for use as anti-infectives; pharmaceutical preparations for the treatment of viral conditions, namely human immunodeficiency virus (HIV), human papilloma virus (HPV), respiratory syncytial virus (RSV), hepatitis, herpes genitalis, herpes labialis, herpes simplex virus, varicella-zoster virus, Epstein-Barr virus and cytomegalovirus; pharmaceutical preparations for the treatment and prevention of respiratory diseases and disorders and their symptoms; pharmaceutical preparations for the treatment of immune system related diseases and disorders, namely immunosuppressants; pharmaceutical preparations for the treatment of immunologic diseases and disorders namely, autoimmune diseases and disorders; pharmaceutical preparations for the treatment of atherosclerosis; pharmaceutical preparations for the treatment and prevention of metabolic related diseases and disorders namely disorders of the endocrine system, namely growth and thyroid disorders, diabetes, metabolic syndrome, obesity, weight loss and weight management; pharmaceutical preparations for the treatment and prevention of cardiovascular, cardiopulmonary, cardio-renal and renal diseases and disorders; pharmaceutical preparations for the prevention and treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammation and inflammatory related diseases and disorders namely arthritis, rheumatoid arthritis, inflammatory bowel diseases, inflammatory connective tissue diseases, vasculitis, synovitis; pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain, bone pain and fatigue; pharmaceutical preparations for the treatment of blood-related diseases and disorders namely thrombocytopenia, coagulation disorders, bleeding disorders, platelet disorders, blood vessel disorders, sickle-cell disease and its related disorders, anemias, sepsis and infections in and of the blood; pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases, osteoporosis, spinal diseases, back pain, gout, fractures, sprains, osteogenesis imperfecta, muscle wasting (cachexia), renal osteodystrophy, cartilage injuries, joint replacement and osteoarthritis; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely dermatitis, skin and skin structure infections namely bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema and sexually transmitted diseases; pharmaceutical preparations for the treatment of hormonal related diseases and disorders namely hypogonadism, testosterone disorders, androgen disorders and estrogen disorders; pharmaceutical preparations for the treatment of gastrointestinal related diseases and disorders namely irritable bowel disorders and symptoms, digestive disorders and acid related disorders, namely acidifiers to increase levels of gastric acid to decrease stomach pH for human purposes; pharmaceutical preparations for the treatment of sexual dysfunction namely erectile dysfunction, male and female sexual dysfunction disorders namely arousal disorder, pain disorder, desire disorder and orgasm disorder; pharmaceutical preparations for the treatment of genitourinary diseases namely urological diseases and disorders; pharmaceutical preparations for the treatment of gynaecological diseases and disorders namely amenorrhoea, dysmenorrheal and infertility; pharmaceutical hormonal preparations namely corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations for the treatment of incontinence, prostate diseases and disorders, bladder diseases and disorders; pharmaceutical preparations for the treatment of sexually transmitted diseases, inflammatory pelvic diseases, vasomotor symptoms, menopausal symptoms, endometriosis, uterine fibroids, Leiomyoma, pre-eclampsia and pre-term labour; pharmaceutical preparations for use in urology; pharmaceutical preparations for the treatment of prostatitis, nephritis, cystitis, vaginitis, renal disease; pharmaceutical preparations for the treatment of premenstrual dysphoric disorder, premenstrual syndrome, male hypogonadism and hormonal disorders namely polycystic ovary syndrome; pharmaceutical preparations for the treatment of hepatological related diseases namely hepatitis, non-alcoholic fatty liver disease (NAFLD), non alcoholic steatohepatitis (NASH), liver fibroids, and cirrhosis; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia (male pattern baldness); pharmaceutical preparations for the treatment of psychiatric diseases and disorders namely mood disorders, anxiety disorders, cognitive disorders, schizophrenia, and psychoses; pharmaceutical preparations for the treatment of damaged skin and tissue namely bee stings, sunburn, rashes, sores, corns, calluses and acne; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of malaria; pharmaceutical preparations for the treatment of tuberculosis; allergy medications; vaccines for human use.;

Linha do tempo do processo

2 eventos

Movimentações mais recentes da marca “VUPLENTIC” publicadas na Revista da Propriedade Industrial (RPI). O detalhe de cada despacho fica na consulta completa.

  1. Andamento21 de jan. de 2026RPI 2872

    Desistência total de designação em razão de renúncia à Inscrição Internacional que afeta o Brasil

    Detalhes na consulta completa
  2. Ação / prazo11 de nov. de 2025RPI 2862

    Publicação de pedido de registro para oposição (exame formal de designação concluído)

    Detalhes na consulta completa

O que fazer se a sua marca se aproxima de "VUPLENTIC"?

Conflitos de marcas no Brasil são resolvidos com base na anterioridade do depósito, nas classes de Nice e no segmento de atuação. O processo tem várias fases e pode ficar complexo quando o nome é parecido ou o mercado se cruza. Uma leitura cuidadosa ajuda a decidir se vale seguir, ajustar ou recuar.

A TrademarkIQ cruza histórico, decisões e padrões de aprovação por classe e setor em uma base com +6 milhões de processos brasileiros. Isso ajuda a enxergar o risco com mais contexto e a encontrar o melhor caminho comercial e jurídico para a sua marca.

Vigilância de marca

Seja avisado antes que vire problema

Monitoramento contínuo: receba um alerta a cada novo depósito que possa colidir com VUPLENTIC ou com a sua marca — a tempo de se opor dentro do prazo.

Monitorar marca

Dados actualizados a partir de uma base com +6 milhões de marcas brasileiras analisadas. Esta página é informativa e não substitui parecer jurídico, mas ajuda a orientar a decisão com mais contexto comercial e técnico.